LIPOFILLING AND ONCOPLASTIC BREAST SURGERY : oncologic safety
|
|
|
- Amberlynn Cummings
- 5 years ago
- Views:
Transcription
1 LIPOFILLING AND ONCOPLASTIC BREAST SURGERY : oncologic safety JY Petit IEO Milan December 13-15, th Annual New York Controversies, Problems & Techniques in Surgery SYMPOSIUM COURSE DIRECTORS Robert Michler, MD; Steven Libutti, MD; Peter Shamamian, MD Controversies, Problems & Techniques in Surgery NO DISCLOSURE This presentation is the intellectual property of the presenter. Contact him for permission to reprint and/or to distribute
2 Immediate remodelling after tumourectomy
3 Indications
4
5 Conservative surgery 40g AL
6 Conservative surgery 60 g AL
7 Conservative surgery 50 g AL
8 Implant BR 40g AL
9 Implant reconstruction 50 g AL
10 1,75 m 46 kil 55 g left breast
11 Breast volume augmentation scar improvement Coleman technique
12
13 90 y old women 40 years after abdominal radiation therapy and non healing sacral pressure sore Dr Sadanori Akita 90% cells to circular area around sore Immediate Pre-op Intraop after debridement 10% cells to sore itself Intra-op after Cell Tx 145 days 14 Days Post Op 25 Days Post Op 41 Days Post Op
14 1994 Osteosarcoma tt Clinical results 2006 lipofilling Local recurrence LR of osteosarcoma 13 y after TT 18 mths after lipofilling
15 Kotaro Yoshimura, M.D.
16 SAFETY OF LIPOFILLING IN BREAST CANCER PATIENTS From the lab to clinical results F.BERTOLINI I.MARTIN PADURA IEO Milan Review Adipose tissue cells, lipotransfer and cancer: A challenge for scientists, oncologists and surgeons Francesco Bertolini a, NOS DISCLOSURE
17 155 Samples FROM LIPOTRANSFER HAVE BEEN PURIFIED COLEMAN TECHNIQUE Abdominal or thigh Human WAT >150 samples F. BERTOLINI S LAB Stromal vascular fraction Enzymatic digestion Purified CD34+ WAT-derived cells Immunomagnetic separation
18 Transplant of a human breast cell line on the mammary gland of a imunodeficient mouse to develop a breast cancer mouse model NSG, Females, 8 weeks old cell suspension in matrigel +blu dye cells suspension injected in the fourth mammary fad pad directly though the nipple 10 6 breast cancer cells 10 6 breast cancer cells + 2x10 5 WAT cells Tumors are detectable at day 7 raise mm3 in days
19 Tumor volume (mm3) Tumor volume (mm3) Adipose derived CD34+ cells promote breast tumor growth in vivo Tumors were bigger when co-transplanted with adipose cells.and this was true with two different breast cell lines Breast cell line 1 (MDA-MB-436) CD34+ Unfractionated Control CD34+, no tumor Days MDA-MB-436 MDA-MB-436 CD34 + WAT cells Breast cell line 2 (HCC1937) Control Days
20 Injection of CD34+WAT-derived cells increases lung metastases WAT cells axillary lympho node metastases primary tumor mastectomy Lung Metastases Controls CD34- injected CD34+ injected lung metastases
21 2012 9/269 with oncologic FU Only 2/9 with a control group (Rigotti - Petit) Only 1 with a cohort study group (Petit)
22 Eur J Surg Oncol May;38(5): Epub 2012 Mar 15. Prospective trial of adipose-derived regenerative cell (ADRC)-enriched fat grafting for partial mastectomy defects: the RESTORE- 2 trial. Pérez-Cano R, Vranckx JJ, Lasso JM, Calabrese C, Merck B, Milstein AM, Sassoon E, Delay E, Weiler-Mithoff EM No local recurrence No control group Very short follow up
23 Annals of Oncology 2011 may breast cancer patients who subsequently underwent lipofilling: Coleman technique 642 matched-patients with similar characteristics who did not undergo a lipofilling.
24 Matching criteriae
25 +6 months Washing out period
26
27 BCT C Invasif mastectomy DCIS p< 0.001
28 CONCLUSION: Matched Cohort Control Study I 1. No evidence of increasing risk of LRR after Lipofilling on the whole population 2- Significant increase of local recurrence rate in the group of intra epithelial neoplasia (DCIS LCIS)
29 EVALUATION OF FAT GRAFTING SAFETY IN PATIENTS WITH INTRA EPITHELIAL NEOPLASIA : A MATCHED COHORT STUDY Jean Yves Petit 1 ; Mario Rietjens 1 ; Edoardo Botteri 2 ; Nicole Rotmensz 2 ; Francesco Bertolini 3 ; Annals of Oncology (in press) 59 IN SITU breast cancer patients who subsequently underwent lipofilling (Coleman technique) 118 IN SITU matched-patients with similar characteristics who did not undergo a lipofilling.
30 Lipofilling n (%) Controls n (%) All patients Age at first surgery (years) Median (range) 46 (30-64) 47 (26-69) Age at baseline (years) Median (range) 49 (33-65) 50 (29-72) p Matching Variable Matching Variable Time to baseline from surgery 1 year years years > 3 years 19 (32.2) 13 (22.0) 10 (17.0) 17 (28.8) 38 (32.2) 26 (22.0) 20 (17.0) 34 (28.8) Matching Variable Histology Year of surgery Type of surgery Estrogen receptor a Progesteron receptor a Grade a Ki-67 % a Her2/neu a Margin status a after quadrantectomy Hormone therapy Estrogen receptor positive Radiotherapy after quadrantectomy DIN LIN Quadrantectomy Mastectomy Positive Negative Positive Negative < Not Overexpressed Overexpressed Negative ( 1mm) Close (< 1mm) Positive Any None Standard ELIOT No 57 (96.6) 2 (3.4) 7 (11.9) 30 (50.9) 22 (37.3) 12 (20.3) 47 (79.7) 44 (80.0) 11 (20.0) 41 (74.6) 14 (25.6) 11 (19.6) 28 (50.0) 17 (30.4) 25 (43.9) 32 (56.1) 34 (64.2) 19 (35.9) 7 (58.3) 3 (25.0) 2 (16.7) 28 (63.6) 16 (36.4) 4 (33.3) 3 (25.0) 5 (41.7) 114 (96.6) 4 (3.4) 18 (15.3) 65 (55.1) 35 (29.7) 24 (20.3) 94 (79.7) 88 (80.0) 22 (20.0) 83 (72.8) 31 (27.2) 17 (14.5) 75 (64.1) 25 (21.4) 55 (48.3) 59 (51.8) 74 (67.3) 36 (32.7) 18 (78.3) 4 (17.4) 1 (4.4) 55 (62.5) 33 (37.5) 6 (25.0) 8 (33.3) 10 (41.7) Matching Variable Matching Variable Matching Variable Matching Variable
31 Local recurrences characteristics Lipofilling Age at baseline Surgery for the primary Location of the primary Yes 46 QUAD QSI DIN Yes 45 QUAD QSE DIN Yes 62 SSM QSE DIN Yes 41 SSM QSI DIN Yes 39 TM QSE DIN Histology of the primary Comedo + Micropapillar y Cribriform + Necrosis Cribriform + Micropapillar y + Necrosis Cribriforme + Micropapillar y + Papillary + Necrosis Cribiforme + micropapillar y + Necrosis Grade Margin Surgery for the relapse Location of the relapse 3 N NSM QSI DIN 3 N NSM QSE DIN + IDC Histology of the relapse Solid + necrosis + comedo Solid + necrosis Grade Lipofilling (CC) Lipofilling location Time from primary surgery to local relapse Time from lipofilling to local relapse 3 64 QSI, QII QSE N WE QSE IDC NR NR 35 QSI,QSE N WE QE DIN NR NR 90 QSI,QSE N WE QSE IDC papillary 1 27 QSI Yes 45 NSM QSI, QII DIN Cribiforme + Solid 3 N WE QSE DIN + IDC Solid + necrosis 3 37 QII,QIE No 39 NSM QI DIN Cribriform + Necrosis 2 N WE Retro areolar DIN Micropapillar y 2 n\a n\a 48 n\a No 45 NSM QSI DIN Cribriform + Micropapillar y + Necrosis 2 N WE No 47 SSM QII DIN Papillary 2 N WE QE Retro areolar DIN DIN + IDC Cribriform + Micropapillar y + Necrosis 2 n\a n\a 65 n\a Cribriform 1 n\a n\a 56 n\a Quadrantectomy Mastectomy 12 (20.3) 47 (79.7) 24 (20.3) 94 (79.7)
32 RISK FACTORS OF LOCO REGIONAL EVENT IN THE LIPOFILLING GROUP At risk (%) Events (5-year cum inc %) All patients 59 6 (17.8) Age at lipofilling < 50 years 30 (50.8) 5 (23.1) 50 years 29 (49.2) 1 (4.7) Histology DIN 57 (96.6) 6 (19.0) LIN 2 (3.4) 0 (0.0) 1 year 19 (32.2) 4 (37.7) Time to baseline years 13 (22.0) 1 (7.7) from surgery years 10 (17.0) 1 (10.0) > 3 years 17 (28.8) 0 (0.0) Type of surgery Quadrantectomy 12 (20.3) 2 (16.7) Mastectomy 47 (79.7) 4 (18.4) Estrogen receptor Positive 44 (80.0) 5 (20.3) Negative 11 (20.0) 1 (9.1) Progesteron Positive 41 (74.6) 4 (14.0) receptor Negative 14 (25.6) 2 (53.6) Grade Ki-67 % Her2/neu Margin status after quadrantectomy Hormone therapy Estrogen receptor positive Radiotherapy after quadrantectomy < Not Overexpressed Overexpressed Negative ( 1mm) Close (< 1mm) Positive Any None Standard ELIOT No 11 (19.6) 28 (50.0) 17 (30.4) 25 (43.9) 32 (56.1) 34 (64.2) 19 (35.9) 7 (58.3) 3 (25.0) 2 (16.7) 28 (63.6) 16 (36.4) 4 (33.3) 3 (25.0) 5 (41.7) 0 (0.0) 3 (21.4) 3 (NA) 1 (4.0) 5 (32.9) 4 (20.0) 2 (10.5) 1 (14.3) 1 (33.3) 0 (0.0) 3 (16.4) 2 (30.0) 1 (25.0) 1 (33.3) 0 (0.0) p a
33 Cumulative Incidence P-value: 0.02 HR Lipo vs No lipo =4.5 (95% CI ) 5-year cumulative incidence: Lipofilling: 18% No Lipofilling: 3% 0.3 LR 0.2 Lipofilling 18% No Lipofilling 3% Years from baseline At risk Lipofilling No Lipofilling
34 Cumulative Incidence Cumulative Incidence Cumulative Incidence Cumulative Incidence Cumulative Incidence Cumulative Incidence Cumulative Incidence Cumulative Incidence Age at lipofilling < 50 years Age at lipofilling >= 50 years P-value: Lipofilling; n=30 No Lipofilling; n= P-value: 0.58 Lipofilling; n=29 No Lipofilling; n= Years from baseline Years from baseline G1 and G2 G Lipofilling; n=39 Lipofilling; n= No Lipofilling; n=92 No Lipofilling; n= P-value: P-value: Years from baseline Years from baseline Ki-67 < 14% Ki-67 >= 14% Lipofilling; n=25 No Lipofilling; n= P-value: P-value: < Lipofilling; n=32 No Lipofilling; n= Years from baseline Years from baseline Quadrantectomy Mastectomy Lipofilling; n=12 No Lipofilling; n= Lipofilling; n=47 No Lipofilling; n= P-value: 0.04 P-value: 0.11 Years from baseline Years from baseline
35 CONCLUSION INCREASING RISK OF LOCAL RECURRENCES AFTER LIPOFILLING IN PATIENTS TREATED FOR NON INVASIVE BREAST CANCER Strength : matched cohort study But conclusion should be considered cautiously: small series short follow up
36 CONCLUSION FURTHER STUDIES ARE REQUIRED ESPECIALLY WITH LIPOFILLING USING STEM CELLS ENHANCEMENT assuming the increasing risk of cancer stimulation with an increasing concentration of stem cells
Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study
BREAST of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study Steven J. Kronowitz, M.D. Cosman Camilo Mandujano, M.D. Jun Liu, M.D., Ph.D. Henry M. Kuerer,
The Case FOR Oncoplastic Surgery in Small Breasts. Barbara L. Smith, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, MA USA
The Case FOR Oncoplastic Surgery in Small Breasts Barbara L. Smith, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, MA USA Changing issues in breast cancer management Early detection
Recent Advances in Breast Cancer Treatment
Recent Advances in Breast Cancer Treatment Pornchai O-charoenrat MD, PhD, FRCST, FICS Professor Chief, Division of Head-Neck & Breast Surgery Department of Surgery, Siriraj Hospital, THAILAND Recent Advances
Locoregional recurrence risk after lipofilling in breast cancer patients
23: 582 588, 2012 doi:10.1093/annonc/mdr158 Published online 24 May 2011 Locoregional recurrence risk after lipofilling in breast cancer patients J. Y. Petit 1 *, E. Botteri 2, V. Lohsiriwat 1,3, M. Rietjens
Related Policies None
Medical Policy MP 7.01.153 BCBSA Ref. Policy: 7.01.153 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Surgery Related Policies None DISCLAIMER Our medical policies are designed for informational
Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates
Ann Surg Oncol (2012) 19:3771 3776 DOI 10.1245/s10434-012-2404-5 ORIGINAL ARTICLE BREAST ONCOLOGY Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the
Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast
Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast Policy Number: 7.01.153 Last Review: 12/2018 Origination: 6/2015 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City
White Rose Research Online URL for this paper: Version: Supplemental Material
This is a repository copy of Complications in DIEP Flap Breast Reconstruction After Mastectomy for Breast Cancer: A Prospective Cohort Study Comparing Unilateral Versus Bilateral Reconstructions. White
NIPPLE SPARING MASTECTOMY
NIPPLE SPARING MASTECTOMY 29th Annual Montefiore-Einstein Controversies in Surgery Symposium Virgilio Sacchini, MD Memorial Sloan-Kettering Cancer Center Professor of Clinical Surgery Weill Cornell Medical
Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
How To Make a Good Mastectomy for Reconstruction Based on the Anatomy. Zhang Jin, Ph.D MD
How To Make a Good Mastectomy for Reconstruction Based on the Anatomy Zhang Jin, Ph.D MD Deputy Director and Professor Tianjin Medical University Cancer Institute and Hospital People s Republic of China
Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate
NEW TECHNIQUES IN BREAST RECONSTRUCTION
NEW TECHNIQUES IN BREAST RECONSTRUCTION J Van Geertruyden and J-V Berthe Plastic Surgery Erasme University Hospital and Clinique Edith Cavell Brussels What s new in breast reconstruction? New materials
Prophylactic Mastectomy & Reconstructive Implications
Prophylactic Mastectomy & Reconstructive Implications Minas T Chrysopoulo, MD PRMA Center For Advanced Breast Reconstruction Prophylactic Mastectomy Surgical removal of one or both breasts to reduce the
Current Strategies in Breast Reconstruction
Current Strategies in Breast Reconstruction Hani Sbitany, MD Assistant Professor of Surgery University of California, San Francisco Division of Plastic and Reconstructive Surgery 12 th Annual School of
Intraoperative. Radiotherapy
Intraoperative Radiotherapy ROBERTO ORECCHIA UNIVERSITY of MILAN & EUROPEAN INSTITUTE of ONCOLOGY & CNAO FOUNDATION Breast Cancer Brescia, 30th September 2011 IORT, very selective technique to intensify
Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015
Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy
complicanze in chirurgia senologica ricostruttiva Tecniche per la prevenzione delle complicanze nelle mastectomie conservative
Il trattamento delle complicanze in chirurgia senologica ricostruttiva Tecniche per la prevenzione delle complicanze nelle mastectomie conservative Dr. Christian Rizzetto UOC Chirurgia Senologica - Breast
Your Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:
Your Guide to the Breast Cancer Pathology Report Key Questions Here are important questions to be sure you understand, with your doctor s help: Your Guide to the Breast Cancer Pathology Report 1. Is this
Fat Grafting: Research Aspects
Fat Grafting: Research Aspects P A U L C E D E R N A, M D P L A S T I C S U R G E R Y F O U N D A T I O N P R E S I D E N T - E L E C T C H I E F, S E C T I O N O F P L A S T I C S U R G E R Y R O B E
Radiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
Breast Reconstruction: Current Strategies and Future Opportunities
Breast Reconstruction: Current Strategies and Future Opportunities Hani Sbitany, MD Assistant Professor of Surgery University of California, San Francisco Division of Plastic and Reconstructive Surgery
Advances in Localized Breast Cancer
Advances in Localized Breast Cancer Melissa Camp, MD, MPH and Fariba Asrari, MD June 18, 2018 Moderated by Elissa Bantug 1 Advances in Surgery for Breast Cancer Melissa Camp, MD June 18, 2018 2 Historical
Breast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
ONCOLOGIC AND COSMETIC CHALLENGES DO NOT ROUTINELY OPPOSE BREAST CONSERVING SURGERY IN RETRO-AREOLA PRIMARY LESIONS
ONCOLOGIC AND COSMETIC CHALLENGES DO NOT ROUTINELY OPPOSE BREAST CONSERVING SURGERY IN RETRO-AREOLA PRIMARY LESIONS SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department of Surgery Nelson R. Mandela
Disclosure. Objectives 03/19/2019. Current Issues in Management of DCIS Radiation Oncology Considerations
Current Issues in Management of DCIS Radiation Oncology Considerations Fariba Asrari, M.D. Director. Johns Hopkins Breast Center at Green Spring Station Department of Radiation Oncology & Molecular Sciences
Supplementary Online Content
Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.
Contralateral Prophylactic Mastectomy with Immediate Reconstruction: Added Benefits, Added Risks
Contralateral Prophylactic Mastectomy with Immediate Reconstruction: Added Benefits, Added Risks Grant W. Carlson Wadley R. Glenn Professor of Surgery Divisions of Plastic Surgery & Surgical Oncology Emory
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
Patients with Nipple-Areola Paget s Disease and Underlying Invasive Breast Carcinoma Have Very Poor Survival: A Matched Cohort Study
Patients with Nipple-Areola Paget s Disease and Underlying Invasive Breast Carcinoma Have Very Poor Survival: A Matched Cohort Study Hong Ling 1,2., Xin Hu 1,2., Xiao-Li Xu 1,3., Zhe-Bin Liu 1,2, Zhi-Min
Disclosure of Relevant Financial Relationships. Breast Pathology Evening Specialty Conference Case #4. Clinical Case: Pathologic Features
Breast Pathology Evening Specialty Conference Case #4 K.P. Siziopikou, MD, PhD Professor of Pathology Director of Breast Pathology and Breast Pathology Fellowship Program Northwestern University Feinberg
Node nega)ve breast cancer: Immediate breast reconstruc)on - An op)on for every pa)ent? Peer Chris)ansen
Node nega)ve breast cancer: Immediate breast reconstruc)on - An op)on for every pa)ent? Peer Chris)ansen Barriers to immediate breast reconstruc)on Concerns about the increased risks of local recurrence
Extending breast conservation and other new oncoplastic techniques
Extending breast conservation and other new oncoplastic techniques Dick Rainsbury BSBR 11-12 November 2013 Liverpool What s the maximum volume of the breast which can be resected during lumpectomy without
Neoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
Genomic Profiling of Tumors and Loco-Regional Recurrence
1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
Current status of breast reconstruction in China: an experience of 951 breast reconstructions from a single institute
Original Article Current status of breast reconstruction in China: an experience of 95 breast reconstructions from a single institute Nai-Si Huang,, Chen-Lian Quan,, Lin-Xiao-Xi Ma,, Jing Si,, Jia-Jian
Maria João Cardoso, MD, PhD
Locally Advanced Breast Cancer Specific Issues in LocorregionalTreatment Surgery, MD, PhD Head Breast Surgeon Breast Unit, Champalimaud Foundation Lisbon, Portugal 1 Conflict of Interest Disclosure No
Invasive Papillary Breast Carcinoma
410 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the
Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction
Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction Aldona J. Spiegel, M.D., and Charles E. Butler, M.D. Houston, Texas Skin-sparing
Breast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016
Breast Cancer: Management of the Axilla in 2016 Greg McKinnon MD FRCSC SON Vancouver Oct 2016 No Disclosures Principle #1 There is no point talking about surgical therapy in isolation. From a patient
Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
BSBR conference Nottingham 10th Nov 2015
BSBR conference Nottingham 10th Nov 2015 Breast imaging after oncoplastic and risk adapted conservation Fiona MacNeill FRCS, MD Breast Surgeon, London With thanks to Miss Katy Green SSM Medical Student
Breast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR
BREAST LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR HISTOLOGY LOBE: (10 in whole breast) LOBULE: (many per lobe) ACINUS/I, aka ALVEOLUS/I: (many per lobule) DUCT(S): INTRA- or
PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
Surgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
Racial/Ethnic Disparities in Second Breast Lesions after DCIS. Graham A. Colditz, MD DrPH Kevin Garza Ying Liu, MD PhD Rosy Luo, PhD Yu Tao, PhD
Racial/Ethnic Disparities in Second Breast Lesions after DCIS Graham A. Colditz, MD DrPH Kevin Garza Ying Liu, MD PhD Rosy Luo, PhD Yu Tao, PhD Why DCIS? DCIS over 45,000 cases per year SEER 18 Cancer
Unexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience
Unexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience NCIN Annual Conference, National Motorcycle Museum June 2008 Dr Gill Lawrence West Midlands Cancer
How can surgeons help the Radiation Oncologists?
How can surgeons help the Radiation Oncologists? Lorna Weir BC Surgical Oncology fall breast cancer update Oct 24, 2009 Disclosure no conflict of interest Outline Introduction OR reports Marking of surgical
Oncoplastic breast surgery in a Danish perspective II: Reconstructive strategy in oncoplastic breast surgery
Oncoplastic breast surgery in a Danish perspective II: Reconstructive strategy in oncoplastic breast surgery Michael Rose, MD Department of Surgery and Plastic Surgery, Hospital of Southwest Jutland, Denmark
Bruno CUTULI Policlinico Courlancy REIMS. WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ
Bruno CUTULI Policlinico Courlancy REIMS WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ XXI CONGRESSO AIRO GENOVA 22.11.2011 INTRODUCTION Due to wide diffusion of mammography,
Basement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and Endocine surgery Daisuke Ota No financial support
RADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
Hypofractionated Radiotherapy for breast cancer: Updated evidence
2 rd Bangladesh Breast Cancer Conference, Dhaka, December 2017 Hypofractionated Radiotherapy for breast cancer: Updated evidence Tabassum Wadasadawala Associate Professor of Radiation Oncology Tata Memorial
The biplanar oncoplastic technique case series: a 2-year review
Original Article The biplanar oncoplastic technique case series: a 2-year review Alexander J. Kaminsky 1, Ketan M. Patel 2, Costanza Cocilovo 1, Maurice Y. Nahabedian 2, Reza Miraliakbari 3 1 INOVA Fairfax
Contents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ
Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5
Ductal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
Nipple Sparing Mastectomy: Tips & Tricks. Rebecca Nelson, MD MSc FRCSC Plastic & Reconstructive Surgeon, Burnaby Hospital
Nipple Sparing Mastectomy: Tips & Tricks Rebecca Nelson, MD MSc FRCSC Plastic & Reconstructive Surgeon, Burnaby Hospital Nipple Sparing Mastectomy (NSM) Introduction & Technique Safety Evidence Indications/Contraindications
Surgical treatment of BRCA mutated patients. Viviana Galimberti MD European Institute of Oncology Milan, Italy
Surgical treatment of BRCA mutated patients Viviana Galimberti MD European Institute of Oncology Milan, Italy No pharmaceutical company funding was used I declare I have no conflicts of interest as regards
Use of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment
Use of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment Barbara L. Smith, MD, PhD Professor of Surgery, Harvard Medical School Division of Surgical Oncology Massachusetts
My Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
Treatment options for the precancerous Atypical Breast lesions. Prof. YOUNG-JIN SUH The Catholic University of Korea
Treatment options for the precancerous Atypical Breast lesions Prof. YOUNG-JIN SUH The Catholic University of Korea Not so benign lesions? Imaging abnormalities(10% recall) lead to diagnostic evaluation,
Classification System
Classification System A graduate of the Breast Oncology training program should be able to care for all aspects of disease and/or provide comprehensive management. When referring to a discipline of training
Breast Surgery: Yesterday, Today and Tomorrow
Breast Surgery: Yesterday, Today and Tomorrow Baptist Hospital Gladys L. Giron, MD, FACS October 11,2014 Homestead Hospital Baptist Children s Hospital Doctors Hospital Baptist Cardiac & Vascular Institute
Radiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015
Radiation Treatment for Breast Cancer Melissa James Radiation Oncologist August 2015 OUTLINE External Beam Radiation treatment. (What is Radiation, doctor?) Role of radiation. (Why am I getting radiation,
10 reasons why it makes sense to rename DCIS to minimise overtreatment? PRO: Mike Dixon OBE Edinburgh Breast Unit
10 reasons why it makes sense to rename DCIS to minimise overtreatment? PRO: Mike Dixon OBE Edinburgh Breast Unit 10 reasons why it makes sense to rename DCIS to minimise overtreatment? PRO: Mike Dixon
Case Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
Incorporating Nipple-Sparing Mastectomy Into Your Practice. Michael Howard, MD, FACS Karol A Gutowski, MD, FACS
Incorporating Nipple-Sparing Mastectomy Into Your Practice Michael Howard, MD, FACS Karol A Gutowski, MD, FACS 1 Disclosures Michael Howard, MD Scientific Advisor, EO2 Concepts Karol Gutowski, MD Speaker's
ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
When do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
Ms Katherine Gale. Oncoplastic Breast Surgeon Waitemata District Health Board Auckland
Ms Katherine Gale Oncoplastic Breast Surgeon Waitemata District Health Board Auckland 16:30-17:25 WS #167: Update on Breast Cancer 17:35-18:30 WS #179: Update on Breast Cancer (Repeated) Update on Breast
Educational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery
Educational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery Goal The goal of the Breast Surgery rotation is to develop the knowledge, skills and attitudes necessary to evaluate,
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Oncoplastic and Reconstructive Surgery
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Oncoplastic and Reconstructive Surgery Plastic-reconstructive aspects after mastectomy Versions 2002 2017: Audretsch / Bauerfeind
Diseases of the breast (2 of 2) Breast cancer
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
NIPPLE SPARING PRE-PECTORAL BREAST RECONSTRUCTION
NIPPLE SPARING PRE-PECTORAL BREAST RECONSTRUCTION 42 yo female healthy athlete Right breast mass. Past medical history: none Family history: aunt with Breast cancer Candidates for nipple-sparing mastectomy
The evolution of mastectomies in the oncoplastic breast surgery era
Perspective The evolution of mastectomies in the oncoplastic breast surgery era Gustavo Zucca-Matthes 1,2, Andrea Manconi 3, Rene Aloísio da Costa Viera 1,2, Rodrigo Augusto Depieri Michelli 2, Angelo
Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
Resection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland
Resection Margins in Breast Conserving Surgery Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland Breast Conserving Surgery 1 Probably one of the most important innovation in cancer surgery
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
Ca in situ e ormonoterapia. Discussant : LORENZA MARINO
Ca in situ e ormonoterapia Discussant : LORENZA MARINO Ca in situ e ormonoterapia Quali fattori di rischio? Radioterapia? Ormonoterapia? BCS Recurrence rates (FUP 13-20y) Cuzick, Lancet Oncol.2011; 12(1):
BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
ARROCase - April 2017
ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein
Paget's Disease of the Breast: Clinical Analysis of 45 Patients
236 Paget's Disease of the Breast: Clinical Analysis of 45 Patients Mingfian Yang Hao Long Jiehua He Xi Wang Zeming Xie Department of Thoracic Oncology, Cancer Center of Sun Yat-sen University, Guangzhou
Protocol. Reconstructive Breast Surgery/Management of Breast Implants
Protocol Reconstructive Breast Surgery/Management of Breast Implants Medical Benefit Effective Date: 04/01/14 Next Review Date: 11/18 Preauthorization Yes Review Dates: 02/07, 02/08, 01/09, 01/10, 01/11,
Comparison of two techniques of interstitial pulsed dose rate boost brachytherapy in conservative treatment of breast cancer
Original article Original articles Comparison of two techniques of interstitial pulsed dose rate boost brachytherapy in conservative treatment of breast cancer Krystyna Serkies, MD, PhD 1, Zofia Tarnawska,
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
Original article Annals of Oncology 15: 1633 1639, 2004 doi:10.1093/annonc/mdh434 Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
University of Groningen. Local treatment in young breast cancer patients Joppe, Enje Jacoba
University of Groningen Local treatment in young breast cancer patients Joppe, Enje Jacoba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
METASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER
Trakia Journal of Sciences, No 4, pp 7-76, 205 Copyright 205 Trakia University Available online at: http://www.uni-sz.bg ISSN 33-7050 (print) doi:0.5547/tjs.205.04.02 ISSN 33-355 (online) Original Contribution
Mammo-50 Eligibility Queries
Mammo-50 Eligibility Queries Are patients who have received either neo-adjuvant or adjuvant chemo, radiotherapy or been part of another trial, ie OPTIMA, FAST FORWARD excluded from entry? Any patients
Table of contents. Page 2 of 40
Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the
Image guided core biopsies:
Recommendations on the Surgical, Radiologic and Pathologic Approaches to Breast Disease: Using best practices based on multidisciplinary methodologies developed through the Allina Breast Committee. Image
Results of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
A Combined Practice. Why Its Worked. Barriers to Breast Reconstruction. As a breast oncologist the patient gets seemless care
A Combined Practice A Combined Breast Oncology and Plastic Surgery Practice Why It Works Anne M. Wallace, MD, FACS Director, Comprehensive Breast Health Center Professor of Clinical Surgery, Surgical Oncology
Plastic Reconstructive Aspects after Mastectomy
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Plastic Reconstructive Aspects after Mastectomy Plastic Reconstructive Aspects after Mastectomy Version 2002: Brunnert Version
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer